| 1 |
32963612 | Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells in vitro. | 2020 Nov |
1 |
| 2 |
30605061 | Gefitinib Represses JAK-STAT Signaling Activated by CRTC1-MAML2 Fusion in Mucoepidermoid Carcinoma Cells. | 2019 |
8 |
| 3 |
29552290 | ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells. | 2018 Feb 23 |
4 |
| 4 |
29637613 | Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib. | 2018 Aug |
2 |
| 5 |
29033690 | Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells. | 2017 |
1 |
| 6 |
29088281 | Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3. | 2017 |
1 |
| 7 |
25501339 | Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib. | 2015 Feb |
4 |
| 8 |
25662161 | Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells. | 2015 May 15 |
2 |
| 9 |
24268810 | Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression. | 2014 Apr |
1 |
| 10 |
24486412 | Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. | 2014 May |
2 |
| 11 |
24687941 | Nanoimmunoassay to Detect Responses in Head and Neck Cancer: Feasibility in a Mouse Model. | 2014 Jul |
1 |
| 12 |
25058005 | Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. | 2014 |
2 |
| 13 |
25228008 | Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells. | 2014 Oct |
1 |
| 14 |
25400829 | Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines. | 2014 |
2 |
| 15 |
23270470 | Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines. | 2013 Mar |
1 |
| 16 |
23959460 | Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells. | 2013 Oct |
1 |
| 17 |
24071646 | Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells. | 2013 Sep 26 |
1 |
| 18 |
21544845 | Regulation of cigarette smoke-mediated mucin expression by hypoxia-inducible factor-1α via epidermal growth factor receptor-mediated signaling pathways. | 2012 Apr |
1 |
| 19 |
22101421 | The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. | 2012 Feb |
1 |
| 20 |
22414764 | Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. | 2012 Jul |
1 |
| 21 |
22863020 | Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. | 2012 Nov |
1 |
| 22 |
21878657 | Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. | 2011 Nov |
3 |
| 23 |
21961726 | Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. | 2011 Oct 2 |
1 |
| 24 |
22037177 | Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. | 2011 |
1 |
| 25 |
19956829 | A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. | 2010 Jan |
1 |
| 26 |
20026060 | Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. | 2010 Jan 22 |
1 |
| 27 |
20097187 | MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. | 2010 Mar 30 |
2 |
| 28 |
18409071 | Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. | 2009 Mar |
1 |
| 29 |
19380191 | Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells. | 2009 Oct 8 |
1 |
| 30 |
18172786 | Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. | 2008 |
2 |
| 31 |
18544565 | Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. | 2008 Jul |
2 |
| 32 |
19001445 | Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. | 2008 Nov |
3 |
| 33 |
19020749 | Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. | 2008 Dec |
1 |
| 34 |
17237287 | Molecular correlates of gefitinib responsiveness in human bladder cancer cells. | 2007 Jan |
3 |
| 35 |
17317832 | A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. | 2007 Feb 15 |
3 |
| 36 |
17513607 | ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. | 2007 May |
4 |
| 37 |
16003751 | Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. | 2006 Jan 1 |
4 |
| 38 |
16441427 | Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib. | 2006 Feb |
2 |
| 39 |
16508686 | Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro. | 2006 Feb |
2 |
| 40 |
16585207 | Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. | 2006 Apr 1 |
5 |
| 41 |
16322337 | Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. | 2005 Dec |
1 |
| 42 |
15269164 | Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. | 2004 Jul 15 |
4 |
| 43 |
12966092 | Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. | 2003 Nov 21 |
1 |